ID   HDLM-2
AC   CVCL_0009
SY   HD-LM-2; HDLM2
DR   CLO; CLO_0003671
DR   CLDB; cl1580
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473364
DR   BioSample; SAMN10988513
DR   CCLE; HDLM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01064
DR   ChEMBL-Cells; CHEMBL3308234
DR   ChEMBL-Targets; CHEMBL2366231
DR   Cosmic; 924110
DR   Cosmic; 988701
DR   Cosmic; 1013909
DR   Cosmic; 1086355
DR   Cosmic; 1278832
DR   Cosmic; 1289699
DR   Cosmic; 1290220
DR   Cosmic; 1432040
DR   Cosmic; 2276322
DR   Cosmic; 2464309
DR   Cosmic-CLP; 924110
DR   DepMap; ACH-000267
DR   DSMZ; ACC-17
DR   GDSC; 924110
DR   GEO; GSM335390
DR   GEO; GSM381298
DR   GEO; GSM499724
DR   GEO; GSM499732
DR   GEO; GSM552430
DR   GEO; GSM646534
DR   GEO; GSM887064
DR   GEO; GSM888134
DR   GEO; GSM1669870
DR   IARC_TP53; 23613
DR   IGRhCellID; HDLM2
DR   LINCS_LDP; LCL-2007
DR   PharmacoDB; HDLM2_521_2019
DR   PRIDE; PXD000589
DR   Wikidata; Q54882175
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2602652;
RX   PubMed=2690233;
RX   PubMed=3713248;
RX   PubMed=8558920;
RX   PubMed=9685479;
RX   PubMed=12581897;
RX   PubMed=17065008;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25894527;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   http://www.proteinatlas.org/learn/cellines
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Doubling time: ~70-75 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: TP53 p.Ser261fs c.?(782delins) (PubMed=17065008).
CC   Omics: Cell surface proteome.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.09%; Native American=0%; East Asian, North=1.64%; East Asian, South=0%; South Asian=0.05%; European, North=62.14%; European, South=35.08% (PubMed=30894373).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 12
ST   D5S818: 11
ST   D7S820: 8,10
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_M693 ! HDLM-1
OI   CVCL_M697 ! HDLM-3
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2602652; DOI=10.1007/978-3-642-83781-4_8;
RA   Drexler H.G., Gignac S.M., Hoffbrand A.V., Leber B.F., Norton J.,
RA   Lok M.-S., Minowada J.;
RT   "Characterization of Hodgkin's disease derived cell line HDLM-2.";
RL   Recent Results Cancer Res. 117:75-82(1989).
//
RX   PubMed=2690233; DOI=10.1007/978-3-642-83781-4_5;
RA   Schaadt M., Burrichter H., Pfreundschuh M., Schell-Frederick E.,
RA   Tesch H., Fonatsch C., Stein H., Diehl V.;
RT   "Biology of Hodgkin cell lines.";
RL   Recent Results Cancer Res. 117:53-61(1989).
//
RX   PubMed=3713248; DOI=10.1016/0145-2126(86)90084-6;
RA   Drexler H.G., Gaedicke G., Lok M.-S., Diehl V., Minowada J.;
RT   "Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of
RT   morphology, immunological and isoenzyme profiles.";
RL   Leuk. Res. 10:487-500(1986).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=12581897; DOI=10.1016/S0165-4608(02)00656-8;
RA   Berglund M., Flordal E., Gullander J., Lui W.-O., Larsson C.,
RA   Lagercrantz S., Enblad G.;
RT   "Molecular cytogenetic characterization of four commonly used cell
RT   lines derived from Hodgkin lymphoma.";
RL   Cancer Genet. Cytogenet. 141:43-48(2003).
//
RX   PubMed=17065008; DOI=10.1080/10428190600667721;
RA   Feuerborn A., Moritz C., Von Bonin F., Dobbelstein M., Trumper L.,
RA   Sturzenhofecker B., Kube D.;
RT   "Dysfunctional p53 deletion mutants in cell lines derived from
RT   Hodgkin's lymphoma.";
RL   Leuk. Lymphoma 47:1932-1940(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//